pSivida Corp. (NASDAQ:PSDV) Files An 8-K Other Events
Item 8.01. Other Events.

On March 2, 2017, pSivida Corp. (the “Company”) entered into a funded feasibility study agreement with a leading biopharmaceutical company. Under phase one of the work plan, the Company’s proprietary Durasert™ sustained release drug technology will be formulated with certain of the biopharmaceutical company’s proprietary molecules to determine potential pre-clinical benefits. Pending results of the formulation research, the biopharmaceutical company may elect to proceed with phase two of the pre-clinical work plan, which will involve combining Durasert with one or more of the proprietary molecules evaluated in phase one of the feasibility study agreement.

About pSivida Corp. (NASDAQ:PSDV)

pSivida Corp. develops drug delivery products primarily for the treatment of chronic eye diseases. The Company operates through the biotechnology sector segment. The Company has developed three products for treatment of back-of-the-eye diseases, which include Medidur for posterior segment uveitis, its lead product candidate that is in pivotal Phase III clinical trials; ILUVIEN for diabetic macular edema (DME), its lead licensed product that is sold in the United States and European Union (EU) countries, and Retisert. Medidur is designed to treat chronic non-infectious uveitis affecting the posterior segment of the eye (posterior segment uveitis). ILUVIEN is an injectable micro-insert that provides treatment of DME from a single injection. Retisert is an implant that provides treatment of posterior segment uveitis. Its product development program is focused on utilizing its two technology platforms, Durasert and Tethadur, to deliver drugs and biologics to treat chronic diseases.

pSivida Corp. (NASDAQ:PSDV) Recent Trading Information

pSivida Corp. (NASDAQ:PSDV) closed its last trading session 00.00 at 1.71 with 190,962 shares trading hands.